West Pharmaceutical Services, Inc. (WST) Stock Price & Analysis

West Pharmaceutical Services, Inc. (WST) closed at USD 394.03 on Thursday, October 22, 2026, up 0.14% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 393.48; the Oct 22, 2026 session ranged USD 389.17–397.16 on volume of 679,905 shares. Market capitalization is $27.73B, with a 52-week range of USD 223.83–397.16 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:37 UTC.

Also available as compact Markdown for AI agents: nexqual.com/WST.md

Key facts (WST)

• Last four reported quarters (through Jun 30, 2026): revenue $3.33B, net income $565M (17.0% margin), free cash flow $437M (SEC filings).
• Valuation: P/E 49.1x (avg 44.7x at the last 3 fiscal year-ends), EV/EBITDA 31.9x, net cash $233M.
• 2 of 80 tracked superinvestors hold WST (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
• Insider open-market sales, last ~7 months: 4 Form 4 filings, $6.6M; 3 not under a Rule 10b5-1 plan ($3.9M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (16 analysts), mean target USD 413.73 (range 340–459).
• Total return with dividends: 1Y +28.6% vs S&P 500 +14.9%; 5Y -5.2% vs S&P 500 +80.3%.
• Next earnings: 2026-10-29, EPS estimate USD 2.2, revenue estimate $827M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (WST)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (WST)

P/E 49.1x · P/S 8.3x · EV/EBITDA 31.9x · EV/Sales 8.3x · P/FCF 63.5x · P/B 9.3x · FCF yield 1.58% · Earnings yield 2.04% · Dividend yield (paid, TTM) 0.23% · Buyback yield (TTM) 1.64% · Net cash $233M · EV $27.5B

P/E at fiscal year-ends: Dec 2025 40.5x, Dec 2024 49.0x, Dec 2023 44.7x.

Superinvestors (SEC 13F-HR, Q2 2026) (WST)

2 of 80 tracked investors hold WST. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (WST)

1 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (WST)

Consensus Buy (mean 2.00 on a 1–5 scale), 16 analysts; mean target USD 413.73 (low 340, high 459).

Rating changes, last 120 days:

Total return (dividends reinvested) (WST)

WST revenue by business segment (quarter ended Jun 30, 2026)

WST revenue by region (fiscal year ended Dec 31, 2025)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

WST suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 17, 2026.

Companies that name WST in their SEC reports

WST customer concentration

In the period ended Dec 31, 2025, a single direct customer accounted for 15.8% of revenue, per the company's 10-K filed Feb 17, 2026. The company does not name it.

WST company outlook (results filed Jul 23, 2026)

• “As a result of our team's strong execution in the second quarter and improved outlook, we are increasing our full-year 2026 guidance." Proprietary Products Segment Net sales of $722.6 million grew by 16.6% and increased 15.5% on an organic basis. • High-Value Product ("HVP") Components net sales of $424.1 million increased 19.4% and rose 18.4% on an organic basis.”
• “Full-Year 2026 Financial Guidance • The Company is increasing its full-year 2026 net sales guidance range to $3.345 billion to $3.38”

Quoted word-for-word from the SEC 8-K results press release.

WST analyst estimates and revisions

WST options: expected move

Options price a move of about ±10.8% (±$42.75) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±11% on average.

30-day implied volatility 46.7% vs 21.6% realized over the last 30 trading days. Put/call ratio (volume) 0.08. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:37 UTC)

Technical Analysis (WST)

Nexqual's technical model rates WST "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:37 UTC.

Analyst Ratings (WST)

Wall Street analysts rate WST "Buy" based on 16 analysts, with a mean price target of USD 413.73 (range USD 340–459), per Nexqual as of October 23, 2026 at 10:37 UTC.

Earnings (WST)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Financials & Fundamentals (WST)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Financial Health Score (WST)

Nexqual rates West Pharmaceutical Services, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:37 UTC.

Ownership (WST)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Leadership (WST)

West Pharmaceutical Services, Inc. is led by Michel Lagarde, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:37 UTC.

Major Backers & Investors (WST)

Notable institutional backers of West Pharmaceutical Services, Inc. include FMR, LLC, Fidelity, Artisan Partners Limited Partnership, according to Nexqual as of October 23, 2026 at 10:37 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

From West Pharmaceutical Services, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)

Key Strengths & Strategy (as disclosed to the SEC)

• Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions.
• Our Proprietary Products reportable segment offers elastomers & primary containment, drug delivery devices, integrated systems, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers.
• Our Proprietary Products customers primarily include many of the major biologic, generic, and pharmaceutical drug companies in the world, which incorporate our components and other offerings into their injectable products for distribution to the point of care and ultimate end-user, the patient.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to regulation by governments around the world, and if these regulations are not complied with, existing and future operations may be curtailed, and we could be subject to liability.
• Changes in the regulation of drug products and devices may increase competitive pressure and adversely affect our business.
• We utilize tax rulings and other agreements to obtain certainty in treatment of certain tax matters. These rulings and agreements expire from time to time and may be extended when certain conditions are met or terminated if certain conditions are not met. The impact of any changes in conditions would be the loss of certainty in treatment thus potentially impacting our effective income tax rate.
• We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm and other adverse business consequences.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:37 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt